Gyre Therapeutics, Inc. (GYRE)
| Market Cap | 698.76M -5.1% |
| Revenue (ttm) | 109.82M -3.4% |
| Net Income | -19.91M |
| EPS | -0.22 |
| Shares Out | 106.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,160 |
| Open | 6.70 |
| Previous Close | 6.68 |
| Day's Range | 6.54 - 6.70 |
| 52-Week Range | 5.44 - 9.42 |
| Beta | 4.82 |
| Analysts | Strong Buy |
| Price Target | 18.67 (+183.31%) |
| Earnings Date | Aug 7, 2026 |
About GYRE
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated l... [Read more]
Financial Performance
In 2025, Gyre Therapeutics's revenue was $116.59 million, an increase of 10.24% compared to the previous year's $105.76 million. Earnings were $5.03 million, a decrease of -58.40%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for GYRE stock is "Strong Buy." The 12-month stock price target is $18.67, which is an increase of 183.31% from the latest price.
News
Gyre Therapeutics Earnings release: Q2 2026
Gyre Therapeutics released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Gyre Therapeutics Quarterly report: Q2 2026
Gyre Therapeutics has published its Q2 2026 quarterly earnings report on August 7, 2026.
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by Chi...
Gyre Therapeutics Appoints Three New Members to its Board of Directors
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with opera...
Gyre Therapeutics Registration statement: Registration filing
Gyre Therapeutics filed a registration statement on July 13, 2026, providing details about a securities offering with the SEC.
Gyre Therapeutics Registration statement: Registration filing
Gyre Therapeutics filed a registration statement on June 23, 2026, providing details about a securities offering with the SEC.
Gyre Therapeutics files to sell 30.22M shares of common stock for holders
06:03 EDT Gyre Therapeutics (GYRE) files to sell 30.22M shares of common stock for holders
Gyre Therapeutics Transcript: AGM 2026
Shareholders voted on four key proposals, all of which received sufficient support to pass. No questions were raised, and the meeting concluded with confirmation that final vote results will be filed with the SEC.
Gyre Therapeutics Slides: Corporate presentation
Gyre Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm
Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) ("Gyre") on behalf of the company's long-term shareholders. The ...
Gyre Therapeutics announces China NMPA acceptance of F351 NDA
Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation, or CDE, of China’s National Medical Products Administration, or NMPA, has accepted its new drug application, or NDA, for F351…
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operat...
Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year
Reports Q1 revenue $22.52M, consensus $31.61M. “Building on our successful pre-NDA meeting with China’s CDE at the beginning of the year, we are particularly encouraged by the NMPA’s priority review…
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to...
Gyre Therapeutics Earnings release: Q1 2026
Gyre Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Gyre Therapeutics Quarterly report: Q1 2026
Gyre Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflamm...
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics Proxy statement: Proxy filing
Gyre Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Gyre Therapeutics’ liver fibrosis candidate granted priority review in China
Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, or NMPA, has granted priority review status to the New Drug Application for ...
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operation...
Gyre Therapeutics reports Q4 EPS (2c), consensus 1c
Reports Q4 revenue $37.2M, consensus $35.44M. “2026 is expected to be a pivotal regulatory year for Gyre as we advance Hydronidone toward conditional approval in China following our alignment with…
Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
The company anticipates that 2026 will be a transition period, during which it plans to prioritize regulatory activities, including preparation for the planned NDA submission of Hydronidone. In additi...